Skip to main content
. 2011 Jan 28;183(10):1322–1335. doi: 10.1164/rccm.201008-1276OC

Figure 6.

Figure 6.

Effect of polyinosinic:polycytidylic acid [poly(I:C)] on vascular endothelial growth factor (VEGF)–induced mucus metaplasia. Wild-type (VEGF transgene negative [Tg−]) and transgenic (VEGF Tg+) mice were treated with poly(I:C) (30 μg unless otherwise indicated) or vehicle [poly(I:C)−], transgene activation was accomplished with doxycycline (dox), and bronchoalveolar lavage (BAL) was undertaken. In (A), periodic acid–Schiff staining was performed. In (B–D), BAL mucin 5AC (MUC5AC) accumulation was assessed by slot and immunoblot analysis. In (A) and (B), poly(I:C) treatment was initiated 1 day before dox and both were then continued for 14 days. In (C), poly(I:C) was administered 2 days after dox, and poly(I:C) and dox were continued for 14 days. In (D) dox was started, poly(I:C) treatment was initiated 2 weeks later, and dox and poly(I:C) were continued for an additional 2 weeks. The noted data are representative of a minimum of four similar evaluations.